XTX Topco Ltd Makes New $341,000 Investment in Caribou Biosciences, Inc. (NASDAQ:CRBU)

XTX Topco Ltd acquired a new stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 208,162 shares of the company’s stock, valued at approximately $341,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. lifted its position in Caribou Biosciences by 66.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 17,024 shares of the company’s stock valued at $88,000 after purchasing an additional 6,798 shares during the period. Entropy Technologies LP acquired a new position in shares of Caribou Biosciences in the 1st quarter valued at about $113,000. Pale Fire Capital SE purchased a new stake in shares of Caribou Biosciences in the fourth quarter worth about $162,000. Bayesian Capital Management LP acquired a new stake in Caribou Biosciences during the first quarter worth about $151,000. Finally, Walleye Trading LLC purchased a new position in Caribou Biosciences during the first quarter valued at approximately $155,000. Institutional investors and hedge funds own 77.51% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on CRBU shares. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research note on Tuesday, September 3rd. Royal Bank of Canada restated an “outperform” rating and set a $14.00 price target on shares of Caribou Biosciences in a research report on Wednesday, August 7th. Finally, Evercore ISI downgraded shares of Caribou Biosciences from an “outperform” rating to an “inline” rating and decreased their price objective for the stock from $13.00 to $3.00 in a research report on Monday, June 3rd. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.25.

Caribou Biosciences Stock Performance

Caribou Biosciences stock opened at $1.94 on Friday. The company’s fifty day moving average price is $2.08 and its 200 day moving average price is $2.90. The stock has a market capitalization of $175.22 million, a P/E ratio of -1.34 and a beta of 2.29. Caribou Biosciences, Inc. has a 1 year low of $1.50 and a 1 year high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Tuesday, August 6th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.04. The business had revenue of $3.46 million during the quarter, compared to analysts’ expectations of $3.31 million. Caribou Biosciences had a negative net margin of 372.78% and a negative return on equity of 34.76%. Sell-side analysts predict that Caribou Biosciences, Inc. will post -1.76 EPS for the current year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.